NASDAQ:GWPH - GW Pharmaceuticals PLC- Stock Price, Forecast & News

GW Pharmaceuticals PLC- trades on the NASDAQ under the ticker symbol "GWPH."

GW Pharmaceuticals PLC- (NASDAQ:GWPH) issued its earnings results on Tuesday, November, 5th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.87) by $0.39. The biopharmaceutical company had revenue of $90.97 million for the quarter, compared to the consensus estimate of $86.84 million. GW Pharmaceuticals PLC- had a negative return on equity of 23.04% and a negative net margin of 26.80%. View GW Pharmaceuticals PLC-'s Earnings History.

GW Pharmaceuticals PLC- is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for GW Pharmaceuticals PLC-.

12 brokerages have issued 1-year price objectives for GW Pharmaceuticals PLC-'s shares. Their forecasts range from $134.00 to $238.00. On average, they anticipate GW Pharmaceuticals PLC-'s share price to reach $198.80 in the next year. This suggests a possible upside of 73.6% from the stock's current price. View Analyst Price Targets for GW Pharmaceuticals PLC-.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GW Pharmaceuticals PLC- in the last year. There are currently 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for GW Pharmaceuticals PLC-.

Media headlines about GWPH stock have been trending extremely negative this week, InfoTrie Sentiment reports. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. GW Pharmaceuticals PLC- earned a news impact score of -4.5 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future. View News Stories for GW Pharmaceuticals PLC-.

GW Pharmaceuticals PLC- saw a increase in short interest during the month of December. As of December 13th, there was short interest totalling 5,760,000 shares, an increase of 5.5% from the November 28th total of 5,460,000 shares. Based on an average daily trading volume, of 783,300 shares, the days-to-cover ratio is currently 7.4 days. Approximately 18.8% of the shares of the stock are sold short. View GW Pharmaceuticals PLC-'s Current Options Chain.

Some companies that are related to GW Pharmaceuticals PLC- include Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), GALAPAGOS NV/S (GLPG), Elanco Animal Health (ELAN), Mylan (MYL), Teva Pharmaceutical Industries (TEVA), Beigene (BGNE), Bausch Health Companies (BHC), Ono Pharmaceutical (OPHLF), Catalent (CTLT), Ionis Pharmaceuticals (IONS), Sarepta Therapeutics (SRPT), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO) and Amarin (AMRN).

Based on aggregate information from My MarketBeat watchlists, some companies that other GW Pharmaceuticals PLC- investors own include Canopy Growth (CGC), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Netflix (NFLX), Aurora Cannabis (ACB), Cronos Group (CRON), Tesla (TSLA), Zynerba Pharmaceuticals (ZYNE) and Tilray (TLRY).

GW Pharmaceuticals PLC-'s stock is owned by a number of of retail and institutional investors. Top institutional investors include AdvisorShares Investments LLC (0.08%), Rothschild Investment Corp IL (0.06%), Janney Montgomery Scott LLC (0.04%), Independent Investors Inc. (0.03%), Landsberg Bennett & Dubbaneh LLC (0.02%) and Zurcher Kantonalbank Zurich Cantonalbank (0.01%). Company insiders that own GW Pharmaceuticals PLC- stock include Adam D George, Cabot Brown, Catherine J Mackey, Christopher J Tovey, Douglas B Snyder, Geoffrey W Dr Guy, James Noble, Julian S Gangolli, Justin D Gover, Scott M Giacobello, Volker Knappertz and William A Waldegrave. View Institutional Ownership Trends for GW Pharmaceuticals PLC-.

GWPH stock was sold by a variety of institutional investors in the last quarter, including Exane Derivatives, Steward Partners Investment Advisory LLC, Horrell Capital Management Inc. and NEXT Financial Group Inc. Company insiders that have sold GW Pharmaceuticals PLC- company stock in the last year include Adam D George, Cabot Brown, Catherine J Mackey, Christopher J Tovey, Douglas B Snyder, Geoffrey W Dr Guy, James Noble, Julian S Gangolli, Justin D Gover, Scott M Giacobello, Volker Knappertz and William A Waldegrave. View Insider Buying and Selling for GW Pharmaceuticals PLC-.

GWPH stock was acquired by a variety of institutional investors in the last quarter, including AdvisorShares Investments LLC, Independent Investors Inc., Landsberg Bennett & Dubbaneh LLC, Janney Montgomery Scott LLC, Zurcher Kantonalbank Zurich Cantonalbank , Campbell & CO Investment Adviser LLC, Wedbush Securities Inc. and J.W. Cole Advisors Inc.. View Insider Buying and Selling for GW Pharmaceuticals PLC-.

Shares of GWPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of GWPH stock can currently be purchased for approximately $114.51.

GW Pharmaceuticals PLC- has a market capitalization of $3.54 billion and generates $12.74 million in revenue each year. The biopharmaceutical company earns $-79,880,000.00 in net income (profit) each year or ($10.56) on an earnings per share basis. GW Pharmaceuticals PLC- employs 791 workers across the globe.View Additional Information About GW Pharmaceuticals PLC-.

The official website for GW Pharmaceuticals PLC- is http://www.gwpharm.com/.

GW Pharmaceuticals PLC-'s mailing address is SOVEREIGN HOUSE VISION PARK HISTON, CAMBRIDGE X0, CB24 9BZ. The biopharmaceutical company can be reached via phone at 44-12-2326-6800 or via email at [email protected]